Myriad Genetics Inc (MYGN)
Return on equity (ROE)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | -127,300 | -116,000 | -155,200 | -234,600 | -263,300 | -274,400 | -248,200 | -146,200 | -112,000 | -77,300 | -17,600 | -8,200 | -27,200 | -63,800 | -103,600 | -154,300 | -230,000 | -194,100 | -199,500 | -148,300 |
Total stockholders’ equity | US$ in thousands | 701,100 | 731,700 | 740,500 | 760,000 | 783,200 | 683,400 | 735,200 | 835,200 | 885,800 | 916,600 | 947,400 | 950,100 | 967,800 | 968,600 | 902,500 | 875,200 | 879,900 | 909,300 | 918,200 | 967,200 |
ROE | -18.16% | -15.85% | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -6.59% | -11.48% | -17.63% | -26.14% | -21.35% | -21.73% | -15.33% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-127,300K ÷ $701,100K
= -18.16%
Myriad Genetics Inc's return on equity (ROE) has exhibited a declining trend over the analyzed period, starting from negative values and gradually deteriorating further. The ROE was notably negative in the initial periods, ranging from -15.33% to -26.14%. However, there was a slight improvement noted in the subsequent quarters, with ROE values ranging from -2.81% to -11.48%.
Despite this temporary improvement, the company's ROE once again started decreasing from March 31, 2022, onwards. The most significant drop in ROE was observed in June 30, 2023, where it reached -33.76%, indicating a sharp decline in the profitability derived from shareholders' equity. This negative trend continued into the following quarters, with ROE values ranging from -18.16% to -40.15% by December 31, 2024.
Overall, the consistent negative ROE figures signify that Myriad Genetics Inc has been struggling to generate sustainable returns on its equity capital, which may raise concerns among investors and stakeholders regarding the firm's financial health and operational efficiency.
Peer comparison
Dec 31, 2024